• 76600 Citations
  • 135 h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Comment/debate
2019

Tyrosine kinase inhibitor-associated fibrothorax

Adrianza, A. M., Jimenez, C. A., Aldana, G. L., Pozo, L., Cortes, J. E. & Sagar, A. E. S., Jan 1 2019, In : American Journal of Respiratory and Critical Care Medicine. 199, 11, 1 p.

Research output: Contribution to journalComment/debate

2017

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, J. M., Yarranton, G. T., Walling, J. M. & Lancet, J. E., Aug 2017, In : Leukemia Research. 59, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Erratum: A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials (Leukemia (2017) 31 2 (318-324))

Montalban-Bravo, G., Huang, X., Naqvi, K., Jabbour, E., Borthakur, G., DiNardo, C. D., Pemmaraju, N., Cortes, J., Verstovsek, S., Kadia, T., Daver, N., Wierda, W., Alvarado, Y., Konopleva, M., Ravandi, F., Estrov, Z., Jain, N., Alfonso, A., Brandt, M., Sneed, T. & 8 others, Chen, H. C., Yang, H., Bueso-Ramos, C., Pierce, S., Estey, E., Bohannan, Z., Kantarjian, H. M. & Garcia-Manero, G., Jul 1 2017, In : Leukemia. 31, 7, 1 p.

Research output: Contribution to journalComment/debate

Open Access
2015

Errata: Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy (Blood (2015) 126, 2 (222-232))

Cho, B. S., Zeng, Z., Mu, H., Wang, Z., Konoplev, S., McQueen, T., Protopopova, M., Cortes, J., Marszalek, J. R., Peng, S. B., Ma, W., Davis, R. E., Thornton, D. E., Andreeff, M. & Konopleva, M., Aug 20 2015, In : Blood. 126, 8, 1 p.

Research output: Contribution to journalComment/debate

Open Access
2014

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: An emerging entity with a poor prognosis

Jabbour, E., Ghanem, H., Huang, X., Ravandi, F., Garcia-Manero, G., O'brien, S., Faderl, S., Pierce, S., Choi, S., Verstovsek, S., Brandt, M., Cortes, J. & Kantarjian, H., Apr 2014, In : Clinical Lymphoma, Myeloma and Leukemia. 14, 2, p. 93-97 5 p.

Research output: Contribution to journalComment/debate

9 Scopus citations
1 Scopus citations
2012

Bosutinib in the treatment of chronic myelogenous leukemia

Cortes, J., Nov 1 2012, In : Clinical Advances in Hematology and Oncology. 10, 11, p. 736-737 2 p.

Research output: Contribution to journalComment/debate

3 Scopus citations

Chronic myeloid leukemia: The race is yet to be won

Cortes, J., May 15 2012, In : CMAJ. 184, 8, p. 857-858 2 p.

Research output: Contribution to journalComment/debate

Open Access

CML: The good, the better, and the difficult choices

Cortes, J., Nov 8 2012, In : Blood. 120, 19, p. 3866-3867 2 p.

Research output: Contribution to journalComment/debate

3 Scopus citations

The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

Gibbons, D. L., Pricl, S., Kantarjian, H., Cortes, J. & Quintás-Cardama, A., Jan 15 2012, In : Cancer. 118, 2, p. 293-299 7 p.

Research output: Contribution to journalComment/debate

50 Scopus citations
2011
26 Scopus citations

Erratum: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172/JCI35721)

Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W. & Druker, B. J., Mar 1 2011, In : Journal of Clinical Investigation. 121, 3, 1 p.

Research output: Contribution to journalComment/debate

Open Access
1 Scopus citations

Erratum: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond (Nature Reviews Drug Discovery (2011) 10 (127-140))

Quintás-Cardama, A., Kantarjian, H., Cortes, J. & Verstovsek, S., Apr 1 2011, In : Nature Reviews Drug Discovery. 10, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
3 Scopus citations
2010

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (Cancer (2009) 115 (551-160))

Kantarjian, H. M., Larson, R. A., Guilhot, F., O'Brien, S. G., Mone, M., Rudoltz, M., Krahnke, T., Cortes, J. & Druker, B. J., Aug 1 2010, In : Cancer. 116, 15, 1 p.

Research output: Contribution to journalComment/debate

2009

T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1

Cortes, J. & de Keersmaecker, K., Jul 27 2009, In : Leukemia and Lymphoma. 50, 3, p. 321-322 2 p.

Research output: Contribution to journalComment/debate

1 Scopus citations
2008

Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure

Jabbour, E., Cortes, J. & Kantarjian, H., Oct 1 2008, In : American Journal of Hematology/ Oncology. 7, 10

Research output: Contribution to journalComment/debate

2006

Erratum: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia (Cancer (2006) 106 (120-127))

Thomas, D. A., Sarris, A. H. & Cortes, J., Apr 1 2006, In : Cancer. 106, 7, 1 p.

Research output: Contribution to journalComment/debate

Keeping up with rapid change

Cortes, J., Jan 1 2006, In : Current Hematologic Malignancy Reports. 1, 1, 1 p.

Research output: Contribution to journalComment/debate

Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

Kantarjian, H., Giles, F., O'Brien, S., Cortes, J., Ottmann, O. G., Wunderle, L., Wassmann, B., Hoelzer, D., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Dugan, M., Alland, L., Hochhaus, A., Bhalla, K., Albitar, M. & Griffin, J. D., Jul 1 2006, In : Cancer Biology and Therapy. 5, 7, 1 p.

Research output: Contribution to journalComment/debate

2005

Farnesyl transferase inhibitors in myeloid disorders: Commentary

Stone, R. M. & Cortes, J. E., Dec 12 2005, In : ONCOLOGY. 19, 8, p. 1049-1050+1053-1054

Research output: Contribution to journalComment/debate

2004

Erratum: Phase I study of bortezomib in refractory or relapsed acute leukemias (Clinical Cancer Research (May 15, 2004) 10 (3371-3377))

Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Ruiz, S. L., Guerciolini, R., Wright, J. & Kantarjian, H., Dec 15 2004, In : Clinical Cancer Research. 10, 22, 1 p.

Research output: Contribution to journalComment/debate

1 Scopus citations
2000

Erratum: Chronic myelogenous leukaemia with p185(BCR/ABL) expression: Characteristics and clinical significance (British Journal of Haematology (1999) 107 (581-586))

Farhad, R., Cortes, J., Albitar, M., Arlinghaus, R., Guo, J. Q., Talpaz, M. & Kantarjian, H. M., Mar 22 2000, In : British Journal of Haematology. 108, 2, 1 p.

Research output: Contribution to journalComment/debate